Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Mol Oncol. 2011 Feb;5(1):5-23. doi: 10.1016/j.molonc.2010.11.003. Epub 2010 Nov 24.
Breast cancer is a heterogeneous disease in terms of histology, therapeutic response, dissemination patterns to distant sites, and patient outcomes. Global gene expression analyses using high-throughput technologies have helped to explain much of this heterogeneity and provided important new classifications of cancer patients. In the last decade, genomic studies have established five breast cancer intrinsic subtypes (Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like) and a Normal Breast-like group. In this review, we dissect the most recent data on this genomic classification of breast cancer with a special focus on the Claudin-low subtype, which appears enriched for mesenchymal and stem cell features. In addition, we discuss how the combination of standard clinical-pathological markers with the information provided by these genomic entities might help further understand the biological complexity of this disease, increase the efficacy of current and novel therapies, and ultimately improve outcomes for breast cancer patients.
乳腺癌在组织学、治疗反应、远处转移模式和患者预后方面存在异质性。使用高通量技术的全球基因表达分析有助于解释这种异质性，并为癌症患者提供了重要的新分类。在过去十年中，基因组研究已经确定了五种乳腺癌内在亚型（Luminal A、Luminal B、HER2 富集型、Claudin-low、基底样）和一个正常乳腺样组。在这篇综述中，我们剖析了乳腺癌这种基因组分类的最新数据，特别关注 Claudin-low 亚型，该亚型似乎富含间充质和干细胞特征。此外，我们还讨论了如何将标准临床病理标志物与这些基因组实体提供的信息相结合，以帮助进一步了解该疾病的生物学复杂性，提高现有和新型疗法的疗效，并最终改善乳腺癌患者的预后。
